Reply to 'Aspirin as a painkiller in patients with a high cardiovascular risk profile'

Anne-Marie Schjerning^{1

2}, Patricia McGettigan³, Gunnar H Gislason^{4

5}

Affiliations

¹ Department of Cardiology, Zealand University Hospital, Roskilde, Denmark.
² The Danish Heart Foundation, Copenhagen, Denmark.
³ William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
⁴ The Danish Heart Foundation, Copenhagen, Denmark. gg@heart.dk.
⁵ Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark. gg@heart.dk.

Comment

Anne-Marie Schjerning et al. Nat Rev Cardiol. 2020 Sep.

. 2020 Sep;17(9):609-610.

doi: 10.1038/s41569-020-0399-3.

Anne-Marie Schjerning^{1

2}, Patricia McGettigan³, Gunnar H Gislason^{4

5}

¹ Department of Cardiology, Zealand University Hospital, Roskilde, Denmark.
² The Danish Heart Foundation, Copenhagen, Denmark.
³ William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
⁴ The Danish Heart Foundation, Copenhagen, Denmark. gg@heart.dk.
⁵ Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark. gg@heart.dk.

No abstract available

Comment on

Cardiovascular effects and safety of (non-aspirin) NSAIDs.
Schjerning AM, McGettigan P, Gislason G. Schjerning AM, et al. Nat Rev Cardiol. 2020 Sep;17(9):574-584. doi: 10.1038/s41569-020-0366-z. Epub 2020 Apr 22. Nat Rev Cardiol. 2020. PMID: 32322101 Review.
Aspirin as a painkiller in patients with a high cardiovascular risk profile.
Spiegel R. Spiegel R. Nat Rev Cardiol. 2020 Sep;17(9):609. doi: 10.1038/s41569-020-0398-4. Nat Rev Cardiol. 2020. PMID: 32472110 No abstract available.

1. Spiegel, R. Aspirin as a painkiller in patients with a high cardiovascular risk profile. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-020-0398-4 (2020). - DOI - PubMed - PMC
1. Schjerning, A. M., McGettigan, P. & Gislason, G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-020-0366-z (2020). - DOI - PubMed - PMC
1. NHS Digital. Prescription cost analysis – England, 2018 [PAS]. NHS Digital https://digital.nhs.uk/data-and-information/publications/statistical/pre... (2019).
1. Forder, S., Voelker, M. & Lanas, A. Gastrointestinal safety of aspirin for a high-dose, multiple-day treatment regimen: a meta-analysis of three randomized controlled trials. Drugs R D 16, 263–269 (2016). - DOI
1. Huang, E. S., Strate, L. L., Ho, W. W., Lee, S. S. & Chan, A. T. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am. J. Med. 124, 426–433 (2011). - DOI